Soluble stability

The ability to identify stable and soluble human antibody fragments, coupled with the potential upside from an unpartnered lead program, has enabled ESBATech AG to attract CHF50 million ($41 million) in a tranched series B venture round from an international syndicate of VCs with a focus on late-stage investments.

Antibody fragments, essentially the binding pockets of antibodies, are less stable when taken out of the context of the larger protein and also have a tendency to aggregate, which can be immunogenic. Under these circumstances, ESBATech's ability to create drug-like compounds was key to bringing new members into the syndicate...